⚗️ Retatrutide: The Triple-Agonist Era and the End of Metabolic Willpower

On May 21, 2026, Eli Lilly's investor relations team pushed out a press release that, if you were paying attention, marked the quiet ending of an era. In TRIUMPH-1, the pivotal Phase 3 obesity trial for a molecule called retatrutide, participants on the 12 mg dose lost an average of 28.3% of their body weight over 80 weeks. In the pre-specified extension out to 104 weeks... for those with severe obesity, BMI ≥35 at baseline, the number climbed to 30.3%. Eighty-five pounds. Two years. One weekly injection.

For twenty years, that level of durable weight loss was accessible only through bariatric surgery... a procedure that reroutes your intestines, requires anesthesia and hospitalization, carries a permanent surgical footprint, and remains, statistically, wildly underutilized because most people would rather remain obese than have their stomach stapled. Retatrutide replicates that outcome with a subcutaneous peptide.

This is not another incremental drug story. This is the point on the curve where pharmacology quietly caught up with surgery and then began to pass it. And, more importantly, it is the point where "willpower"... the moral centerpiece of Western attitudes about weight for a century... became a much smaller variable in the equation than we had assumed.

What Retatrutide Is

Retatrutide (Lilly research code LY3437943) is a once-weekly, subcutaneous synthetic peptide. Structurally, it descends from the same design lineage as tirzepatide (Mounjaro / Zepbound), Lilly's dual GLP-1/GIP receptor agonist that has already reshaped the metabolic drug market. The difference is a third receptor... glucagon... and that single addition changes almost everything about what the molecule does inside the body.

Regulatory status matters here. As of July 2026, retatrutide is not approved anywhere in the world. It is only legally available inside Lilly's Phase 3 trial program, the TRIUMPH series... which has enrolled more than 5,800 participants across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, MASLD/MASH, and dedicated cardiovascular and renal outcomes trials. NDA submission is widely expected in Q4 2026. If the FDA grants standard review, approval lands late 2027; a priority review compresses that to mid-2027. Commercial launch, in any scenario, is a 2027-2028 event.

Which means we are having this conversation in the strange, useful window where the science is essentially settled but the drug is not yet on the shelf. That window is worth using.

The Three Receptors: Why Triple Agonism Actually Matters

To understand why retatrutide produces the numbers it does, you have to look at each receptor as an independent metabolic lever and then look at what happens when you pull them together.

GLP-1: satiety and glycemic control

Glucagon-like peptide-1 is the incretin hormone your gut releases when it senses nutrients. It has three jobs relevant here: it slows gastric emptying (so food sits in your stomach longer), it triggers glucose-dependent insulin release from the pancreas (only when blood sugar is elevated, which is why native GLP-1 doesn't cause hypoglycemia), and, most importantly for weight loss... it signals to satiety centers in the hypothalamus and brainstem that you're full. Semaglutide (Ozempic/Wegovy) is a pure GLP-1 receptor agonist. That single mechanism, at 2.4 mg weekly, produces about 14.9% weight loss over 68 weeks in the STEP 1 trial. That was miraculous by the standards of 2021.

GIP: insulin sensitivity and adipocyte biology

Glucose-dependent insulinotropic polypeptide is the other major incretin. Its role in weight biology was contested for years... GIP receptor agonism, antagonism, and mixed signals have all been proposed as beneficial. What tirzepatide (SURMOUNT-1: -20.9% at 72 weeks; head-to-head SURMOUNT-5: 20.2% vs semaglutide's 13.7%) established is that adding GIP agonism to GLP-1 agonism materially improves both efficacy and, arguably, tolerability. GIP signaling appears to modulate adipocyte insulin sensitivity, participate in fat metabolism, and buffer some of the GI side effects that limit GLP-1 dose escalation.

Glucagon: energy expenditure and the liver

This is the differentiator, and it is the part of retatrutide's design that most changes what the drug is doing to your body.

Glucagon is the hormone every med student learns as "the opposite of insulin"... released by pancreatic alpha cells to raise blood sugar when you're fasting. That framing is not wrong, but it is dramatically incomplete. Glucagon receptor activation, at the doses retatrutide provides, does several other things that matter enormously:

• It increases hepatic fat oxidation. Glucagon signaling in the liver drives fatty acid beta-oxidation. This is why retatrutide produces the most dramatic reduction in liver fat of any drug ever tested against MASLD. In Sanyal et al.'s Phase 2a MASLD trial published in Nature Medicine in 2024, the 12 mg dose produced approximately 86% mean relative reduction in liver fat at 48 weeks. Roughly 90% of participants achieved complete steatosis resolution (liver fat <5%). No drug has ever done that.
• It raises basal energy expenditure. Glucagon increases resting metabolic rate, the biological equivalent of turning up the pilot light. GLP-1 monotherapy and GLP-1/GIP dual agonists lose weight primarily by suppressing appetite. Retatrutide loses weight both by suppressing appetite and by increasing the caloric floor at which your body burns fuel. This is why the weight-loss curve keeps compounding through 80-104 weeks rather than plateauing at 48.
• It cross-modulates protein and lipid metabolism in ways still being characterized. In the Phase 2 data, 72% of participants with baseline prediabetes reverted to normoglycemia by 48 weeks... a rate that appears meaningfully above what weight loss alone would predict.

The counter-argument, historically, has been that glucagon agonism raises blood glucose and worsens diabetes. And it does, if it's the only lever you're pulling. The elegance of the triple design is that GLP-1's glucose-dependent insulin release and GIP's insulin sensitization overwhelm the glucose-raising effect of glucagon, while glucagon's metabolic-rate and hepatic-fat effects are preserved. You get the fat-burning without the hyperglycemia. This is the biological point of the molecule.

The Clinical Data: What the Trials Actually Show

Phase 2: the moment retatrutide became inevitable (Jastreboff, NEJM 2023)

The Phase 2 trial published by Ania Jastreboff and colleagues in the New England Journal of Medicine in August 2023 is the paper that put retatrutide on every metabolic researcher's map. N = 338 adults with obesity, no diabetes. Randomized to placebo or one of four dose targets: 1, 4, 8, or 12 mg weekly.

Two features of that data set jumped out immediately to endocrinologists. First, at 48 weeks the weight-loss curve at 12 mg was still descending, no plateau. Second, the dose-response was smooth and continuous, not showing a diminishing return between 8 mg and 12 mg. Both signals suggested that longer trials at higher doses would produce even larger numbers. That prediction has now been confirmed.

Phase 2 in type 2 diabetes (Rosenstock, Lancet)

A parallel Phase 2 in T2D showed HbA1c reductions of up to −2.0% (some analyses report −2.2%) with weight loss up to −16.9% at 36 weeks, and 82% of participants achieving HbA1c ≤6.5%. T2D populations reliably lose less weight than non-diabetic populations on incretin therapy... the fact that retatrutide still delivered these numbers is significant.

Phase 2 MASLD (Sanyal, Nature Medicine 2024)

The Sanyal et al. substudy using MRI-PDFF to quantify liver fat is arguably the most consequential secondary dataset. Approximately 86% mean relative reduction in hepatic fat at 12 mg over 48 weeks; ~90% of participants achieved complete steatosis resolution. Improvements in ASAT, visceral adipose tissue, insulin sensitivity, serum lipids, and K-18 markers of hepatocyte injury. If those numbers hold in Phase 3, retatrutide becomes the most powerful pharmacological intervention ever demonstrated for the most common chronic liver disease in the developed world.

Cardiometabolic markers (ESC 2024)

Presented at the European Society of Cardiology 2024 meeting: retatrutide reduced non-HDL cholesterol by up to 22.2% at 24 weeks and up to 26.9% at 48 weeks, dose-dependent. Systolic blood pressure, triglycerides, and hsCRP all improved similarly. These are the same markers that predict cardiovascular event reduction from statins and semaglutide, the moving of the needle is the point.

Phase 3 TRIUMPH-4 (osteoarthritis, December 2025)

The first Phase 3 readout, announced by Lilly on December 11, 2025. Adults with obesity/overweight and knee osteoarthritis, no diabetes. The two highest doses (9 mg, 12 mg) over 68 weeks. Both co-primary endpoints hit: weight loss up to an average of 71.2 lbs (~28.7%), and pain reduction on the WOMAC osteoarthritis index up to 4.5 points (~75.8% relative). A weight-loss drug that also functions as a joint-pain drug, because it removes 70 pounds of load from a knee that was carrying it.

Phase 3 TRIUMPH-1 (obesity, May 2026): the pivotal readout

This is the trial that will determine retatrutide's regulatory fate and its market position. Registered as NCT05929066. N = 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes. Baseline average 112.7 kg (248.5 lb), BMI 40.0... genuinely severe obesity. Randomized 1:1:1:1 to placebo, 4 mg, 9 mg, or 12 mg.

Read those bottom three rows again. In a Phase 3 trial of severely obese adults, more than one in four people on 12 mg lost at least 35% of their body weight in 80 weeks. Nearly two in three lost at least 25%. Nearly half lost at least 30%. Sixty-five percent of the 12 mg cohort fell below the BMI threshold for obesity entirely. Thirty-seven percent of those who started with class-3 obesity (BMI ≥40) came out of obesity classification.

The 104-week extension, run in a pre-specified subset of 532 participants who had BMI ≥35 at baseline and had tolerated their assigned dose through week 80, pushed those numbers further. Participants originally assigned to 12 mg, maintained at their maximum tolerated dose, reached −30.3% total body weight loss, averaging 85 lbs from an average baseline of 268 lbs. The placebo group, blindly rolled onto retatrutide at week 80, gained back its 2 percentage points of loss and then went to −19.2% at week 104. Even the placebo arm, once treated, hits a semaglutide-class outcome.

Cardiometabolic secondaries: significant improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity CRP. TRIUMPH-2 (T2D) and TRIUMPH-3 (established cardiovascular disease) read out later in 2026 and will determine the size of the label and the pricing power.

Safety and tolerability

The adverse-event profile in TRIUMPH-1 is what you would expect from an incretin dosed to bariatric-surgery efficacy. At 12 mg versus placebo: nausea 42.4% vs 14.8%; diarrhea 32.0% vs 13.5%; constipation 26.1% vs 10.9%; vomiting 25.3% vs 4.8%. Discontinuation due to adverse events was 11.3% at 12 mg vs 4.9% placebo, non-trivial but manageable, and roughly comparable to the highest tirzepatide doses.

The signals worth watching are the two that are relatively distinctive to retatrutide's mechanism:

• Dysesthesia... abnormal skin sensation, tingling, occurred in 12.5% of the 12 mg arm vs 0.9% of placebo. Most cases were mild-to-moderate and resolved during treatment. The mechanism is not fully characterized but is plausibly linked to glucagon receptor signaling in peripheral nerves. Analysts flagged this as the one novel safety signal, though the clinical significance appears low.
• Cardiovascular... no unexpected signal in topline, but the glucagon-agonism-adds-to-heart-rate concern from earlier dual GLP-1/glucagon molecules means the dedicated cardiovascular outcomes trial matters enormously. Modest resting heart-rate increases have been observed with retatrutide, consistent with other incretin agonists.

The class-warning risks, pancreatitis, gallbladder disease, medullary thyroid carcinoma, gastroparesis, hypoglycemia risk when co-administered with insulin/sulfonylureas, food aspiration during anesthesia... carry over from the GLP-1 class. The FDA will require boxed warnings on par with tirzepatide.

Body composition: the muscle question

Every rapid weight loss modality that has ever existed loses some fraction of the loss as lean mass. Bariatric surgery, ketogenic diets, prolonged fasts, GLP-1 agonists, all of them. The question is how much and whether it matters.

The Lancet Diabetes & Endocrinology body-composition substudy of the retatrutide T2D Phase 2 (published June 2025) found that the proportion of lean mass loss to total weight loss was similar to other obesity treatments... meaning retatrutide is not uniquely sparing but not uniquely destructive either. As a class benchmark, the SURMOUNT-1 body-composition substudy for tirzepatide showed body weight −21.3%, fat mass −33.9%, lean mass −10.9% at 72 weeks. That is a ~1:3 lean-to-fat loss ratio, which is roughly the ratio you would see with any calorie deficit of that magnitude, and it is not, in itself, disastrous, but at the retatrutide levels of loss, absolute lean mass loss can approach the equivalent of a decade or more of aging if you do nothing to counteract it.

This is not an argument against the drug. It is the entire argument for the protocol around it, which we'll get to.

How Retatrutide Compares

Two things about that table matter more than the individual numbers.

First, notice the direction. Adding a receptor adds efficacy. GLP-1 alone → 15%. Add GIP → 21%. Add glucagon → 28-30%. This is not a coincidence; it is a physiological argument that obesity is a multi-receptor, multi-hormone dysregulation, and that hitting more of the system produces better results. It also suggests that quadruple-agonists... currently on drawing boards at multiple companies, are the next iteration.

Second, the pricing convergence is deliberate. Lilly and Novo are competing on efficacy and access, not on price per dose. If retatrutide launches at $1,200/month cash, and it works nearly twice as well as semaglutide, the per-percentage-point-of-body-weight cost is actually favorable. That math matters when payors do formulary decisions.

The Market: LLY as a Decadal Thematic

The investment case for Eli Lilly at this point is less about a single drug and more about the fact that they are running the definitional franchise of the metabolic era.

Consider the current run-rate. Lilly's Q1 2026 revenue was $19.8 billion, up 56% year-over-year. Mounjaro and Zepbound alone contributed $12.8 billion in the quarter, which annualizes above $50 billion for two products. Lilly raised full-year 2026 revenue guidance to $82-85 billion. The company has already crossed the threshold where GLP-1 franchise revenue exceeds the entire top line of Merck circa 2020.

Retatrutide is additive to that base. It is not cannibalizing Mounjaro/Zepbound in a competitive sense; it is extending the addressable market. There are patients for whom 15-20% weight loss is insufficient (severe obesity, metabolic surgery candidates), patients for whom liver disease is the primary indication (MASLD/MASH is a $30B+ TAM in itself), patients for whom cardiovascular outcomes and kidney protection matter more than pure weight loss. Retatrutide is being developed with a Phase 3 program broad enough to claim label indications across all of these.

Second-order effects... the actual thematic, are where this gets philosophically interesting for investors:

• Food industry. Snack manufacturers, quick-service restaurants, and hyperpalatable-food producers face a demand cliff. If the top 10% of over-consumers each drop 25% of their food intake, the aggregate calorie market shrinks measurably. Coca-Cola, PepsiCo, Kellanova, Krispy Kreme, and casual-dining chains have all disclosed material concerns.
• Healthcare cost curves. Obesity-driven costs... orthopedic replacements, cardiovascular procedures, diabetes management, sleep apnea equipment, dialysis, are the largest cost drivers in US healthcare. A drug that resolves 30% weight loss and reverses prediabetes in 72% of users has the potential to reshape those cost curves within a decade. Insurers, PBMs, and MSSP providers are already rewriting their actuarial assumptions.
• Life insurance. BMI is a major underwriting input. A durable pharmacological intervention that pulls a meaningful chunk of the insured population out of obesity classification reprices mortality curves. This is quietly one of the largest financial services stories of the decade.
• Fitness industry. Counterintuitively, this is bullish. Weight loss creates demand for the aesthetic layer above it... resistance training, physique optimization, longevity protocols. Peloton and Planet Fitness commentary aside, the actual data trend is toward more people in gyms, not fewer, because they finally have bodies that make the gym feel productive rather than punishing.
• Kidney and organ disease. Diabetic nephropathy is the leading cause of dialysis in the US. If retatrutide's kidney outcomes trial (already enrolled) demonstrates renal protection on top of glycemic and weight effects, we are looking at a structural decline in dialysis demand over 20 years.

The competitive landscape

Retatrutide's most direct competitors are not other Lilly drugs, those are complementary... but the pipelines at other developers. The map:

• Novo Nordisk. Semaglutide remains the incumbent; oral semaglutide (Rybelsus, 7 mg/14 mg) is approved; higher-dose oral semaglutide is in trials. Their triple-agonist analog to retatrutide is CagriSema... semaglutide combined with cagrilintide (a long-acting amylin analog)... with Phase 3 data suggesting weight loss in the low 20s, meaningfully behind retatrutide but competitive with tirzepatide. Novo is now behind Lilly on the frontier and knows it.
• Amgen... MariTide. A monthly-injected bispecific antibody-peptide that agonizes GLP-1 while blocking GIP (opposite direction from tirzepatide's GIP agonism). Phase 2 showed weight loss in the low-to-mid 20s at 52 weeks with a distinctive durability profile after discontinuation. The MARITIME Phase 3 program reads out in early 2027. Monthly dosing is a real convenience differentiator; the efficacy question is whether it lands closer to tirzepatide or retatrutide.
• Roche. Acquired Carmot Therapeutics in 2023 for $2.7B up front. CT-388 (dual GLP-1/GIP, injectable) and CT-996 (oral small-molecule GLP-1) are the assets. Late Phase 2 / Phase 3.
• Structure Therapeutics. GSBR-1290... an oral small-molecule GLP-1 agonist. Phase 2 data have been mixed; still a candidate for the "cheaper oral" segment.
• Viking Therapeutics. VK2735, dual GLP-1/GIP, both injectable and oral formulations. Small biotech with disproportionate market attention; a plausible acquisition target.
• Altimmune. Pemvidutide... dual GLP-1/glucagon (no GIP), specifically targeted at MASH. If it works, it becomes a direct comparator to retatrutide on the liver-fat axis.
• Lilly's own oral asset, orforglipron (Foundayo). Approved in 2026 as the first oral non-peptide GLP-1 agonist. Not as potent as injectables, but the oral form is a distribution revolution: no cold chain, no needles, no pens, no compounding pharmacies. This is what breaks the market open globally in low- and middle-income countries.

The strategic picture: Lilly holds three of the top five assets in the category. Novo holds one and a half. Amgen and Roche are the credible challengers with novel mechanisms. Everyone else is a bet on a specific niche.

The Deeper Frame: What Chemical Satiety Means

Now the part of the essay that most GLP-1 write-ups skip.

For most of the last century, obesity in the West was framed as a personal-morality problem. The prevailing model... implicit in cultural assumptions, doctor-patient interactions, magazine covers, gym culture, dating markets, was that if you were fat, you had failed. Failed at discipline. Failed at eating less. Failed at moving more. The moral valence was heavy enough that the actual physiology of hunger... the fact that leptin resistance is real, that the hedonic and homeostatic hunger systems can be permanently dysregulated by ultra-processed food, that BMI is 40-70% heritable, was ignored or minimized.

Retatrutide, in the 12 mg dose, is a decisive falsification of the willpower model. It is a molecule that adjusts a set point. Given the molecule, people who had struggled with weight for decades... who had run every diet, every gym membership, every therapy, simply eat less. They stop thinking about food. The "food noise" that occupied a huge chunk of their cognitive bandwidth just goes quiet. The internal argument they had been losing their whole lives, they now win, because the argument is no longer happening.

This is philosophically enormous. It means that the moral framing was, at least for a large fraction of the affected population, a category error. Willpower was not the missing variable. The missing variable was a hormone signal that some subset of the population had never had the correct amount of. Retatrutide gives them the signal. They behave accordingly.

This is neither a claim that willpower doesn't exist nor a claim that pharmacology is a substitute for character. It is the observation that in specific, biologically well-characterized domains... appetite regulation being the clearest, the substrate of what we called "trying harder" turns out to be a specific molecular signal. When you supply the signal, the "trying" becomes trivial. When the signal is absent, no amount of trying is sufficient.

The compressed-lifespan thesis

Here is what interests me most about the metabolic era. For 50 years, life-expectancy gains in the developed world have been dominated by cardiovascular medicine... statins, hypertension control, revascularization. The next 25 years of life-expectancy gains, on current trajectory, are going to be dominated by metabolic medicine, because metabolic dysfunction is the upstream driver of the cardiovascular, oncologic, hepatic, renal, and neurodegenerative disease that shorten lives.

If retatrutide, and its successors, because there will be quadruple agonists, tissue-selective agonists, and adjunct therapies... reliably resolve obesity, prediabetes, MASLD, and cardiometabolic inflammation in the majority of the population that carries them, then the demographic curve of chronic disease shifts substantially rightward. That is what "compressed morbidity"... Fries' original 1980 hypothesis... actually looks like when it happens. Not immortality. Not radical life extension. Just less time sick before you die.

That is a bigger public-health event than any single antibiotic, any single vaccine, any single class of oncology drug. It is on the order of clean water. It is arriving quietly, one Phase 3 readout at a time.

The longevity nuance: mTOR, autophagy, and muscle

For longevity-focused readers, retatrutide sits in an interesting position with respect to the classical longevity levers. Caloric restriction and fasting extend lifespan in nearly every model organism ever tested, partly through mTOR downregulation and autophagy induction. GLP-1-class drugs produce a pharmacologically-induced caloric deficit, which should, theoretically... do some of the same work. Early observational data on semaglutide and tirzepatide are consistent with this: reduced all-cause mortality, reduced cardiovascular events, reduced cancer incidence in some analyses.

But there is a hard counterpoint: muscle. The single most durable predictor of healthspan in older adults is skeletal muscle mass and function. Sarcopenia, age-related muscle loss... is the mechanism by which people become frail, fall, break hips, lose independence, and die. Any weight-loss intervention that accelerates lean mass loss without an offsetting stimulus is trading longer-term function for shorter-term body composition.

This is the reason the protocol matters. Retatrutide is not a "take the drug, lose the weight, done" intervention. Not if you care about the next 30 years of your life. It is a metabolic amplifier that requires a specific behavioral scaffold to preserve what the drug alone will erode.

The Practical Section: If This Is Your Body

Who this is likely for

• Adults with clinically significant obesity (BMI ≥30, or ≥27 with comorbidities) who have not achieved durable results with lifestyle intervention.
• Type 2 diabetics whose glycemic control and weight are inadequately managed by first- and second-line agents.
• Patients with MASLD/MASH... retatrutide's liver-fat effect is class-leading and may be the primary reason to prefer it over tirzepatide.
• Patients with severe obesity being evaluated for bariatric surgery, as a pharmacological alternative or bridge.

Who this is likely not for

• Athletes and lean individuals using it for aesthetic recomp. The muscle-loss math is unfavorable, and the drug is not designed for a metabolically healthy body.
• Anyone with personal or family history of medullary thyroid carcinoma or MEN 2.
• History of pancreatitis, severe gastroparesis, or major GI dysmotility.
• Pregnancy, planned pregnancy, or breastfeeding.
• Anyone unwilling to run the muscle-preservation protocol described below. If you cannot commit to resistance training and adequate protein, the drug will strip lean mass along with fat, and you will emerge lighter but functionally worse.

The muscle-preservation protocol

This is where the "As Above" audience needs to be direct with itself. If you take retatrutide (or any high-efficacy incretin) without a resistance training program, you are trading long-term function for short-term body composition. Here is the non-optional scaffold:

Peptide-era stacking context

In the frame of a broader optimization stack, retatrutide is a body-composition and metabolic-disease lever. It does not replace but pairs with:

• BPC-157 / TB-500 for tissue repair and injury recovery (context for the training load required to preserve muscle).
• Longevity peptides (epithalon, thymosin alpha, others) in the general longevity stack... different tier, different objective.
• Selective androgen receptor modulators or, in medical contexts, TRT for lean-mass preservation in specific male populations. Not something to do casually.
• The Sovereign Mind stack we've written about elsewhere, nootropics, adaptogens, cognitive peptides... operates independently. Metabolic and cognitive optimization are complementary, not overlapping.

The overall point: retatrutide is one instrument in a larger orchestra. Treating it as a single-solution weight-loss injection is exactly the kind of reductionist framing this journal exists to argue against.

Forward-Looking: What to Watch

Near-term catalysts

• TRIUMPH-2 readout (2026): Retatrutide in obesity + T2D. This determines the diabetes label size and the head-to-head competitiveness against tirzepatide in T2D.
• TRIUMPH-3 readout (2026): Established cardiovascular disease population. If this shows MACE reduction, retatrutide gets a cardiovascular indication comparable to semaglutide's, critical for payor coverage.
• NDA submission (expected Q4 2026): Formal marker of regulatory timeline.
• FDA advisory committee & PDUFA date (2027): Boxed-warning language, dosing schedule, patient population.
• MASH Phase 3 (in flight): If retatrutide is the first drug to reliably resolve MASH histologically, it takes a market that was expected to belong to resmetirom and pemvidutide.
• Amgen MariTide MARITIME readout (early 2027): The most consequential competitive data.

Beyond retatrutide: the next iteration

• Quadruple agonists. Adding an amylin, FGF21, or PYY component to a triple-agonist is already in preclinical development at multiple companies. Amylin adds satiety and delayed gastric emptying without additional glucagon; FGF21 adds direct metabolic effects. Expect a quad in the clinic within 24 months.
• Tissue-selective agonists. Peptides engineered to activate a receptor in one tissue and not another... for example, glucagon receptor activation in liver but not in the heart. Reduces off-target effects and enables higher effective dosing.
• Oral triple agonists. Whether via non-peptide small molecules (the orforglipron model) or via oral peptide delivery technology (permeation enhancers, gastroprotection). Once you have an oral triple, you have global-scale accessibility.
• Biomarker-guided personalized dosing. The peptide era converging with the AI era. Continuous glucose monitors, wearable metabolic tracking, AI-driven dose titration by individual response. This is the actual "personalized medicine" that has been promised for 15 years and is finally becoming operationally feasible.
• Combination regimens. Retatrutide plus a myostatin inhibitor (bimagrumab class) is the obvious pairing for lean-mass preservation. That combination has been floated for years and is technically straightforward, it is a matter of regulatory pathway and payer economics, not science.

... Marc Theiler